186 related articles for article (PubMed ID: 14674703)
41. Omapatrilat limits infarct size and lowers the threshold for induction of myocardial preconditioning through a bradykinin receptor-mediated mechanism.
Ebrahim Z; Baxter GF; Yellon DM
Cardiovasc Drugs Ther; 2004 Mar; 18(2):127-34. PubMed ID: 15162074
[TBL] [Abstract][Full Text] [Related]
42. Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and omapatrilat.
Heudi O; Ramirez-Molina C; Marshall P; Amour A; Peace S; McKeown S; Abou-Shakra F
J Pept Sci; 2002 Nov; 8(11):591-600. PubMed ID: 12487427
[TBL] [Abstract][Full Text] [Related]
43. Vasopeptidase inhibition with omapatrilat increases fluid and protein microvascular permeability in cat skeletal muscle.
Persson J; Morsing P; Grände PO
J Hypertens; 2004 Mar; 22(3):637-44. PubMed ID: 15076171
[TBL] [Abstract][Full Text] [Related]
44. Antihypertensive and antihypertrophic effects of omapatrilat in SHR.
Burrell LM; Droogh J; Man in't Veld O; Rockell MD; Farina NK; Johnston CI
Am J Hypertens; 2000 Oct; 13(10):1110-6. PubMed ID: 11041166
[TBL] [Abstract][Full Text] [Related]
45. Role of basal nitric oxide synthesis in vasoconstrictor hyporeactivity in the perfused rat hindlimb after myocardial infarction: effect of captopril.
Ceiler DL; Nelissen-Vrancken M; De Mey JG; Smits JF
Cardiovasc Res; 1999 Aug; 43(3):779-87. PubMed ID: 10690350
[TBL] [Abstract][Full Text] [Related]
46. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats.
Intengan HD; Schiffrin EL
Hypertension; 2000 Jun; 35(6):1221-5. PubMed ID: 10856267
[TBL] [Abstract][Full Text] [Related]
47. Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects.
McClean DR; Ikram H; Mehta S; Heywood JT; Rousseau MF; Niederman AL; Sequeira RF; Fleck E; Singh SN; Coutu B; Hanrath P; Komajda M; Bryson CC; Qian C; Hanyok JJ;
J Am Coll Cardiol; 2002 Jun; 39(12):2034-41. PubMed ID: 12084605
[TBL] [Abstract][Full Text] [Related]
48. Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction.
Marie C; Mossiat C; Lecomte JM; Schwartz JC; Bralet J
J Pharmacol Exp Ther; 1995 Dec; 275(3):1324-31. PubMed ID: 8531099
[TBL] [Abstract][Full Text] [Related]
49. Vasopeptidase inhibition: a new concept in blood pressure management.
Burnett JC
J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
[TBL] [Abstract][Full Text] [Related]
50. Omapatrilat enhances adrenomedullin's reduction of cardiomyocyte cell death.
Rabkin SW; Klassen SS
Eur J Pharmacol; 2007 May; 562(3):174-82. PubMed ID: 17343842
[TBL] [Abstract][Full Text] [Related]
51. The brain is a possible target for an angiotensin-converting enzyme inhibitor in the treatment of chronic heart failure.
Sato T; Yoshimura R; Kawada T; Shishido T; Miyano H; Sugimachi M; Sunagawa K
J Card Fail; 1998 Jun; 4(2):139-44. PubMed ID: 9730108
[TBL] [Abstract][Full Text] [Related]
52. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.
See F; Thomas W; Way K; Tzanidis A; Kompa A; Lewis D; Itescu S; Krum H
J Am Coll Cardiol; 2004 Oct; 44(8):1679-89. PubMed ID: 15489104
[TBL] [Abstract][Full Text] [Related]
53. Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet.
Gröholm T; Finckenberg P; Palojoki E; Saraste A; Bäcklund T; Eriksson A; Laine M; Mervaala E; Tikkanen I
Hypertens Res; 2004 Aug; 27(8):609-18. PubMed ID: 15492481
[TBL] [Abstract][Full Text] [Related]
54. Renoprotective effects of omapatrilat are mediated partially by bradykinin.
Zhou X; Ono H; Ono Y; Frohlich ED
Am J Nephrol; 2003; 23(4):214-21. PubMed ID: 12789027
[TBL] [Abstract][Full Text] [Related]
55. Vasopeptidase inhibition restores renovascular endothelial dysfunction in salt-induced hypertension.
Quaschning T; D'Uscio LV; Shaw S; Gröne HJ; Ruschitzka F; Lüscher TF
J Am Soc Nephrol; 2001 Nov; 12(11):2280-2287. PubMed ID: 11675404
[TBL] [Abstract][Full Text] [Related]
56. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
Bralet J; Marie C; Mossiat C; Lecomte JM; Gros C; Schwartz JC
J Pharmacol Exp Ther; 1994 Jul; 270(1):8-14. PubMed ID: 8035346
[TBL] [Abstract][Full Text] [Related]
57. Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental congestive heart failure.
Abassi ZA; Yahia A; Zeid S; Karram T; Golomb E; Winaver J; Hoffman A
Am J Physiol Heart Circ Physiol; 2005 Feb; 288(2):H722-8. PubMed ID: 15498826
[TBL] [Abstract][Full Text] [Related]
58. Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension.
Maniu CV; Meyer DM; Redfield MM
Hypertension; 2002 Oct; 40(4):528-34. PubMed ID: 12364358
[TBL] [Abstract][Full Text] [Related]
59. Combination angiotensin converting enzyme and direct renin inhibition in heart failure following experimental myocardial infarction.
Connelly KA; Advani A; Advani S; Zhang Y; Thai K; Thomas S; Krum H; Kelly DJ; Gilbert RE
Cardiovasc Ther; 2013 Apr; 31(2):84-91. PubMed ID: 21884026
[TBL] [Abstract][Full Text] [Related]
60. Renal hemodynamic effects of nonhypotensive doses of angiotensin-converting enzyme inhibitors in hypertension and heart failure rats.
Nelissen-Vrancken HJ; Struijker-Boudier HA; Smits JF
J Cardiovasc Pharmacol; 1992 Feb; 19(2):163-8. PubMed ID: 1376783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
